Relation between Modified Body Mass Index and Adverse Outcomes after Aortic Valve Implantation.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 08 2021
Historique:
received: 14 02 2021
revised: 08 05 2021
accepted: 11 05 2021
pubmed: 5 7 2021
medline: 18 9 2021
entrez: 4 7 2021
Statut: ppublish

Résumé

We aimed to investigate the relationship of modified body mass index (mBMI), the product of BMI and serum albumin, with survival after transcatheter (TAVI) and surgical aortic valve implantation (SAVI). Frailty is associated with poor outcomes after TAVI and SAVI for severe aortic stenosis (AS). However, clinical frailty is not routinely measured in clinical practice due to the cumbersome nature of its assessment. Modified BMI is an easily measurable surrogate for clinical frailty that is associated with survival in elderly cohorts with non-valvular heart disease. We utilized individual patient-level data from a pooled database of the Placement of Aortic Transcatheter Valves (PARTNER) trials from the PARNTER1, PARTNER2 and S3 cohorts. We estimated cumulative mortality at 1 year for quartiles of mBMI with the Kaplan-Meier method and compared them with the log-rank test. We performed Cox proportional hazards modeling to assess the association of mBMI strata with 1-year mortality adjusting for baseline clinical characteristics. A total of 6593 patients who underwent TAVI or SAVI (mean age 83±7.3 years, 57% male) were included. mBMI was independently associated with all-cause one-year mortality with the lowest mBMI quartile as most predictive (HR 2.33, 95% CI 1.80-3.02, p < 0.0001). Notably, mBMI performed as well as clinical frailty index to predict 1-year mortality in this cohort. In conclusion, modified BMI predicts 1-year survival after both TAVI and SAVI. Given that it performed similar to the clinical frailty index, it may be used as a clinical tool for assessment of frailty prior to valve implantation.

Identifiants

pubmed: 34217433
pii: S0002-9149(21)00497-5
doi: 10.1016/j.amjcard.2021.05.023
pii:
doi:

Substances chimiques

Serum Albumin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-100

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Elissa Driggin (E)

New York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, New York. Electronic address: ead9011@nyp.org.

Aakriti Gupta (A)

New York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, New York.

Mahesh V Madhavan (MV)

New York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, New York; Clinical Trial Center, Cardiovascular Research Foundation, New York, New York.

Maria Alu (M)

New York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, New York; Clinical Trial Center, Cardiovascular Research Foundation, New York, New York.

Bjorn Redfors (B)

New York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, New York; Clinical Trial Center, Cardiovascular Research Foundation, New York, New York; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Mengdan Liu (M)

Clinical Trial Center, Cardiovascular Research Foundation, New York, New York.

Shmuel Chen (S)

New York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, New York; Clinical Trial Center, Cardiovascular Research Foundation, New York, New York.

Susheel Kodali (S)

New York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, New York; Clinical Trial Center, Cardiovascular Research Foundation, New York, New York.

Mathew S Maurer (MS)

New York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, New York.

Vinod H Thourani (VH)

Department of Cardiovascular Surgery, Marcus Valve Center, Piedmont Heart Institute, Atlanta, Georgia.

Danny Dvir (D)

Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington.

Michael Mack (M)

Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.

Martin B Leon (MB)

New York-Presbyterian Hospital and the Columbia University Irving Medical Center, New York, New York; Clinical Trial Center, Cardiovascular Research Foundation, New York, New York.

Philip Green (P)

Department of Cardiovascular Medicine, Mount Sinai Morningside Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH